UnitedHealth Group may proceed with its proposal to acquire Change Healthcare, a federal district judge ruled yesterday. The Department of Justice, joined by Minnesota and New York, this year challenged the proposed merger, alleging that the $13 billion transaction would harm competition in commercial health insurance markets and in the market for a vital technology used to process claims and reduce health care costs. AHA had urged DOJ to investigate the proposed acquisition.

“We are disappointed in the court’s decision in the Department of Justice’s lawsuit to block UnitedHealth Group’s acquisition of Change Healthcare,” said AHA General Counsel Melinda Hatton. “We warned that this deal could lead to a massive concentration of sensitive health care data in the hands of a single, powerful owner with an inherent conflict of interest and we remain concerned despite this ruling. We will continue to advocate to protect patients and their health care providers from anticompetitive conduct by commercial health insurance companies and urge federal authorities to remain vigilant.”

Related News Articles

Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…
Headline
The House Appropriations Committee July 10 voted 31-25 to approve legislation that would provide $185.8 billion in funding for the departments of Labor, Health…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
The AHA praised House and Senate leaders in letters June 12 for reintroducing the Improving Seniors’ Timely Access to Care Act, bipartisan legislation that…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Headline
The House Energy and Commerce Oversight and Investigations subcommittee June 4 hosted a hearing to discuss oversight of the 340B Drug Pricing Program. AHA sent…